AlphaMed Pharmaceuticals has successfully expressed a humanized version of the therapeutic protein alpha 1- antitrypsin (AAT)

March 6, 2008 - AlphaMed Pharmaceuticals Corporation announced that the Company has successfully expressed a humanized version of the therapeutic protein alpha 1- antitrypsin (AAT). AlphaMed scientists expressed their recombinant AAT utilizing the Company’s proprietary production system in yeast. The yeast has been genetically altered to produce a molecule “virtually identical” to that which is manufactured by the human body.
“This marks a major milestone for this company and AAT research” stated Joseph McGuirl, AlphaMed’s CEO, “AlphaMed is the first company to develop an AAT molecule with glycosylation that resembles the human protein that is naturally secreted from the liver. The Company has begun to develop products to treat a variety of diseases including hereditary emphysema, COPD, asthma and cystic fibrosis.” Joseph McGuirl joined AlphaMed in July, 2007 and is the former Head of Licensing and Development for Hoffmann- LaRoche... AlphaMed Pharmaceuticals' Press Release -